YM BioSciences Inc.
Mississauga, ON
Company Overview
YM BioSciences Inc. is a cancer drug development company. It licenses research products from academic institutions and other biotechnology companies which it then develops. Its clinical development portfolio includes four different anti-cancer compounds in a number of formulations targeting seven different tumours or stages of cancer.
Drugs in development include tesmilifene, a small molecule chemopotentiator in a pivotal Phase III trial in metastatic and recurrent breast cancer. Tesmilifene has successfully completed an international Phase III trial in metastatic and recurrent breast cancer and a US and Canadian trial in hormone-refractory prostate cancer. The portfolio also includes a humanized monoclonal antibody targeting the EGF receptor that has completed a Phase II trial in Canada and a GnRH anti-cancer vaccine in a Phase I/II clinical trial for hormone-sensitive early-stage prostate cancer. The EGFr MAb has been accorded Orphan Drug designation in Europe and the USA for glioma.
Company Information
Physical Address
400-5045 Orbitor Dr. Bldg. 11
Mississauga, ON L4W 4Y4
CA
Mailing Address
400-5045 Orbitor Dr. Bldg. 11
Mississauga, ON L4W 4Y4
CA
Additional Details
Legal Name: YM BioSciences Inc.
Number of Employees: 15
CA
Clinical Products The company's focus on oncology is directed towards both active and passive immunotherapy, as well as traditional small molecules. All of YMB's clinical products have issued and pending patents protecting the IP.
Contacts
David Allan
Title: Chairman
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Products
-
Norelin Tm
Anti-GnRH anti-cancer vaccine that would target most sex-hormone driven cancers including breast, prostate, uterine fibroids and endometriosis.
-
Tesmilifene *reg.
Small molecule chemopotentiator for all known classes of current chemotherapies in cancer.
- Theracim Hr3
NAICS Categories
Additional Information
325410